BeiGene, Ltd.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 0241.HK has a market cap of 77.67B. Regarding current trading prices, 6160.HK is priced at $145.50, while 0241.HK trades at $4.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 0241.HK's P/E ratio is 48.30. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 0241.HK's ROE of +0.08%. Regarding short-term risk, 6160.HK is more volatile compared to 0241.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 3613.HK has a market cap of 7.30B. Regarding current trading prices, 6160.HK is priced at $145.50, while 3613.HK trades at $8.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 3613.HK's P/E ratio is 14.53. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 3613.HK's ROE of +0.13%. Regarding short-term risk, 6160.HK is more volatile compared to 3613.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 1345.HK has a market cap of 2.54B. Regarding current trading prices, 6160.HK is priced at $145.50, while 1345.HK trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 1345.HK's P/E ratio is 15.64. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 1345.HK's ROE of +0.14%. Regarding short-term risk, 6160.HK is more volatile compared to 1345.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 3390.HK has a market cap of 360.00M. Regarding current trading prices, 6160.HK is priced at $145.50, while 3390.HK trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 3390.HK's P/E ratio is 45.00. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 3390.HK's ROE of +0.01%. Regarding short-term risk, 6160.HK is more volatile compared to 3390.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 1110.HK has a market cap of 330.18M. Regarding current trading prices, 6160.HK is priced at $145.50, while 1110.HK trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 1110.HK's P/E ratio is 7.00. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 1110.HK's ROE of +0.06%. Regarding short-term risk, 6160.HK is less volatile compared to 1110.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 2211.HK has a market cap of 87.32M. Regarding current trading prices, 6160.HK is priced at $145.50, while 2211.HK trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 2211.HK's P/E ratio is 5.45. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 2211.HK's ROE of +0.04%. Regarding short-term risk, 6160.HK is more volatile compared to 2211.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 0348.HK has a market cap of 71.65M. Regarding current trading prices, 6160.HK is priced at $145.50, while 0348.HK trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 0348.HK's P/E ratio is -1.86. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 0348.HK's ROE of +1.89%. Regarding short-term risk, 6160.HK is less volatile compared to 0348.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.

6160.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 6160.HK stands at 213.05B. In comparison, 0574.HK has a market cap of 47.20M. Regarding current trading prices, 6160.HK is priced at $145.50, while 0574.HK trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

6160.HK currently has a P/E ratio of -66.44, whereas 0574.HK's P/E ratio is 1.60. In terms of profitability, 6160.HK's ROE is -0.12%, compared to 0574.HK's ROE of -0.34%. Regarding short-term risk, 6160.HK is less volatile compared to 0574.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 6160.HK.